The presence of immunoreactive glucagon (IRG) in smooth muscle of the cerebral arteries of rats was demonstrated immunohistochemically using two an tisera against pancreatic glucagon, OAL-123 and Unger's 30K. Based on the results and on our previous radioim-
The presence of neuropeptides in the walls of the cerebral arteries has been reported by many inves tigators (Larsson et al., 1976; Lee et al., 1978; Ed vinsson et al., 1980 Ed vinsson et al., , 1981 Ed vinsson et al., , 1983 Matsuyama et al., 1983a,b; Uddman and Edvinsson, 1��3; Yamamoto et al., 1983) . Substance P (SP), vasoactive intestinal polypeptide (VIP), pancreatic polypeptide (PP) , and gastrin-releasing peptide (GRP) have been localized in the neuronal elements, and it has been suggested that they are involved in neurogenic regulation of the cerebral blood flow. However, little is known about the distribution of other pep tides in the walls of the cerebral arteries. In the present study, im munoreactive glucagon (IRG) was found in the walls of the cerebral arteries, particularly within the smooth muscle cells, by means of an indirect im-munoassay and gel filtration study, the smooth muscle cells of the blood vessels may be one of the extrapan creatic sources of IRG in the plasma. Key Words: Ce rebral arteries-Immunoreactive glucagon-Smooth muscle cells. munofluorescence method (Coons, 1958) . The pres ence of IRG in the walls of other arteries has been reported elsewhere (Tanaka et al., 1983) .
MATERIALS AND METHODS
Seven adult male albino rats weighing about 100 g were perfused transcardially with 150 ml of ice-cold saline fol lowed by Zamboni's fixative (Zamboni and De Martino, 1967) under pentobarbital anesthesia (10-30 mg/kg Nem butal, i.p.). Cerebral arteries were excised, postfixed in the same fixative for 2 days, and then immersed in 0.1 M phosphate buffer containing 30% sucrose for 1 day. Frozen sections, 10 f-Lm thick, were cut on a cryostat and processed for the indirect immunofluorescence method of Coons (Coons, 1958) . The sections were incubated in cold phosphate-buffered saline for 10 min before the im munoreaction.
Every third section was incubated for 48 h in a humid atmosphere at 37°C with an antiserum against pancreatic glucagon (OAL-123, Japan Immunoresearch Company, Ltd., or Unger's 30K, Hoechst, Japan, Ltd.) at a dilution of 1: 1 ,000, after which they were rinsed in ice-cold phos phate-buffered saline containing 1% Tr iton X-100 for 15 min and then rinsed in phosphate-buffered saline for a further 10 min. Next the sections were incubated with fluorescein isothiocyanate (FlTC)-conjugated antibodies (Miles Laboratories, Inc.) at a dilution of 1: 1 ,000 under the same conditions as described above, rinsed at 4°C with phosphate-buffered saline for 10 min, and mounted in a phosphate-buffered saline-glycerol mixture. The neighbouring sections were used as the controls; half of them were incubated with absorbed control serum (see below), and the other half were stained with hematox ylin-eosin for exact identification of the regions. In ad dition, several sections were examined in the presence of other peptides such as insulin, somatostatin, and leu-en kephalin in the cerebral vascular walls.
Specificity of antiserum against pancreatic glucagon (OAL-123) C-Te rminal region-specific antiserum against pan creatic glucagon OAL-123 was obtained after immunizing a rabbit with a 19-29 C-terminal fragment pancreatic glu cagon-bovine serum albumin conjugate (Imagawa et aI., 1979) . To remove complement from the antiserum, the antiserum was purified by gel chromatography and IgG molecules were concentrated. The specificity of the an tiserum as evaluated by radioimmunoassay showed less than a 0.1% cross-reaction with gut glucagon and no cross-reaction with other peptides such as somatostatin, substance P, neurotensin, enkephalins, endorphins, cho lecystokinin, luteinizing hormone-releasing hormone, and VIP. Specificity was also tested by an absorption test; antiserum against glucagon, which was absorbed by ex cessive synthetic glucagon (3 IJ-g/ml), was used as the absorption control serum.
RESULTS AND DISCUSSION
In the walls of the large cerebral arteries, such as the vertebral artery, basilar artery, and arteries of the circle of Willis, and in proximal branches of these arteries, prominent IRG was found (Fig. IA) . It was localized exclusively within the cytoplasm of the smooth muscle cells of the tunica media ( Fig.  IA and B) . No IRG was detected in any other ele ment of the arteries. These observations are in con trast to those involving SP, VIP, PP, and GRP, since these compounds are localized only in the neural elements. Distally, smooth muscle cells decreased progressively in number. However, IRG was found within the smooth muscle cells in the walls of all the cerebral arteries examined. Figure Ie shows IRG-positive smooth muscle cells in the walls of intracerebral arterioles. No IRG was seen in the walls of capillaries, including those of the choroid plexus. It should be noted that IRG was detected in the smooth muscle cells of the veins. In the sec tions incubated with the absorption control serum, structures stained by the antiserum were not seen. In addition, no other peptides, such as insulin, so matostatin, or leu-enkephalin, were detected in any of the above tissues.
No differences were observed between the sec tions incubated with OAL-123 and with Unger's 30K antisera, the latter of which is widely used as J Cereb Blood Flow Me/abol, Vol. 4, No.2, 1984 a C-terminal-specific antiserum against pancreatic glucagon.
The present study immunohistochemically re vealed the presence of IRG in the walls of cerebral arteries using different kinds of antisera-OAL-123 and 30K. Using the aorta and the femoral and ulnar arteries of the rat, we had previously shown the presence of IRG in the smooth muscle cells by means of immunohistochemistry (Tanaka et al., 1983) . Furthermore, the IRG content of the above tissues was found to be 320-1,270 pg/g tissue, wet weight. In addition, filtration of the extracted IRG through a Bio-Gel P-30 column yielded a single peak of IRG at 3,500 daltons, the same elution volume of pancreatic glucagon (Tanaka et al., 1983) . These findings, together with the present results, suggest that smooth muscle cells of the vascular wall may be new extrapancreatic sources of IRG, although the possibility that IRG in the plasma diffuses into the vascular wall cannot be wholly excluded. How ever, the latter possibility seems to be unlikely, be cause other pancreatic peptides such as insulin and somatostatin were not detected in the walls of the blood vessels.
There is no evidence to indicate the function of IRG in the vascular wall. As mentioned above, one possibility is that it is an extrapancreatic source of plasma IRG. However, it is possible that IRG in vascular walls may be involved in the neurogenic regulation of cerebral blood flow.
